-
![Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study](https://flcube.com/wp-content/uploads/2025/02/1709-png.avif)
Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has secured RMB150 million (USD20.7 million) in funding from three new investors: Wenzhou Ruili Medical New Consumer Industry Investment Partnership, Shanghai Linjue Enterprise Management, and Shanghai Hanchengming Enterprise Management, as well as its parent company…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
